SAVA

Cassava Sciences Shares Plunge 85% After Co's Alzheimer's Drug Fails in Late-Stage Study

时间:2024-11-25 22:33:07 市场: 综合 美股

关联: SAVA

Cassava Sciences Shares Resume Trading Premarket, Last Down About 85% at $3.94 After Co's Alzheimer's Drug Failed in a Late-Stage Study

时间:2024-11-25 21:25:50 市场: 美股 综合

关联: SAVA

Cassava Sciences Inc: to Discontinue Refocus-Alz

时间:2024-11-25 20:30:06 市场: 美股 综合

关联: SAVA

Cassava Sciences Inc: Also Be Discontinuing Open Label Extension Study

时间:2024-11-25 20:30:06 市场: 美股 综合

关联: SAVA

Cassava Sciences Inc: Simufilam Continued to Demonstrate an Overall Favorable Safety Profile

时间:2024-11-25 20:30:06 市场: 美股 综合

关联: SAVA

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

时间:2024-11-25 20:30:06 市场: 美股 综合

关联: SAVA

Cassava Sciences Inc: Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo

时间:2024-11-25 20:30:06 市场: 美股 综合

关联: SAVA

Cassava Sciences Shares Halted for News Pending Premarket

时间:2024-11-25 20:27:33 市场: 美股 综合

关联: SAVA

Cassava Sciences Reports Q3 2024 Financial and Operating Results

时间:2024-11-07 20:55:00 市场: 美股 综合

关联: SAVA

Cassava Sciences Q3 Basic EPS USD -0.58

时间:2024-11-07 20:55:00 市场: 美股 综合

关联: SAVA